| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,000 | 2,520 | 08:56 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Aclarion, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 07.07. | Aclarion adds Texas Spine Care Center to CLARITY trial | 1 | Investing.com | ||
| 07.07. | Aclarion erweitert CLARITY-Studie um Texas Spine Care Center | 2 | Investing.com Deutsch | ||
| 07.07. | Aclarion, Inc.: Aclarion Announces Texas Spine Care Center as New CLARITY Site | 1 | GlobeNewswire (USA) | ||
| 10.06. | Aclarion, Inc.: Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub | 2 | GlobeNewswire (USA) | ||
| 09.06. | Aclarion partners with PRIA Healthcare on market access program | 4 | Investing.com | ||
| 09.06. | Aclarion, Inc.: Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform | 298 | GlobeNewswire (Europe) | Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK... ► Artikel lesen | |
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 08.06. | Aclarion Comments on Echo Lake News | 1 | Baystreet.ca | ||
| 08.06. | Aclarion, Inc.: Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal | 785 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 08.06. | Aclarion, Inc.: Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting | 195 | GlobeNewswire (Europe) | BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 04.06. | Aclarion, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 03.06. | Aclarion, Inc.: Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation | 2 | GlobeNewswire (USA) | ||
| 01.06. | Aclarion's Nociscan technology used in back pain study | 2 | Investing.com | ||
| 01.06. | Aclarion, Inc.: Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study | 2 | GlobeNewswire (USA) | ||
| 28.05. | Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal | 113 | GlobeNewswire (Europe) | BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary... ► Artikel lesen | |
| 28.05. | Echo Lake Capital Offers To Acquire Aclarion Inc. | 307 | ACCESS Newswire | Offers $4.00 per share in cash plus CVRStock currently trades below the value of its cash and other assetsBelieves company's public shell worth at least another $6 million if Board effected a reverse... ► Artikel lesen | |
| 13.05. | Aclarion, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.05. | Aclarion erweitert CLARITY-Studie um renommierte Privatpraxis für Wirbelsäulenchirurgie | 1 | Investing.com Deutsch | ||
| 07.05. | Aclarion adds Lanman Spinal Neurosurgery to CLARITY trial | 1 | Investing.com | ||
| 07.05. | Aclarion, Inc.: Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment | 1 | GlobeNewswire (USA) |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 370,40 | -0,54 % | Opening Bell: PepsiCo, AstraZeneca, UnitedHealth, Nike, Arista Networks, FuelCell Energy | Die Wall Street zeigt nach der jüngsten Eskalation im Nahen Osten bisher ein gemischtes Bild. Der Dow Jones gab gestern deutlich ab. Der Nasdaq 100 schloss dagegen leicht in der Gewinnzone, Auch heute... ► Artikel lesen | |
| INTUITIVE SURGICAL | 335,95 | +1,08 % | Here's Exactly Why Intuitive Surgical Stock Is Floundering in 2026 | ||
| THERMO FISHER | 466,10 | -0,41 % | Persistence Market Research Pvt. Ltd.: Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG | LONDON, July 8, 2026 /PRNewswire/ -- Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,040 | +3,55 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds | $4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants
SEATTLE, June 12, 2026 /PRNewswire/... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| CENTENE | 60,70 | +0,86 % | Centene Stock Soars 66% YTD: Should Investors Chase the Rally? | ||
| QUIDELORTHO | 15,540 | +0,52 % | QuidelOrtho Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| VERU | 2,300 | -0,43 % | Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... | REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,969 | -1,18 % | Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors | BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest" or "Tempest Therapeutics") today announced the appointment of two independent directors, Drake... ► Artikel lesen | |
| NANO-X IMAGING | 1,065 | +0,47 % | NANO-X IMAGING LTD: New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026 | New SCCT abstracts from Brigham and Women's Hospital highlight the performance and clinical utility of Nanox.AI's FDA-cleared cardiac AI solution, showing high agreement with expert assessment and its... ► Artikel lesen | |
| FULGENT GENETICS | 17,800 | 0,00 % | Fulgent reports interim data for cancer drug FID-007 trial | ||
| LANTHEUS | 89,80 | +0,22 % | Lantheus Holdings, Inc.: Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide) | BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,510 | -6,48 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor | SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering... ► Artikel lesen | |
| OMNICELL | 40,200 | -0,50 % | KeyBanc reiterates Omnicell stock rating on Titan XT launch | ||
| AMN HEALTHCARE SERVICES | 28,000 | -4,76 % | Why AMN Healthcare Services (AMN) is a Top Momentum Stock for the Long-Term |